Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - Nov 9, 2022 Form 3 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person
Stock symbol
ACRV
Transactions as of
Nov 9, 2022
Transactions value $
$0
Form type
3
Date filed
11/9/2022, 07:51 PM
Previous filing
Aug 3, 2021
Next filing
Nov 21, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACRV Series B Preferred Stock Nov 9, 2022 Common Stock 888K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock is convertible into shares of Common Stock, on a 1-for-2.466 basis, into the number of shares of Common Stock shown in column 3 without payment of further consideration at any time at the holder's election and will convert immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.